CN112755029A - 治疗癌症/抑制转移 - Google Patents

治疗癌症/抑制转移 Download PDF

Info

Publication number
CN112755029A
CN112755029A CN202110087549.9A CN202110087549A CN112755029A CN 112755029 A CN112755029 A CN 112755029A CN 202110087549 A CN202110087549 A CN 202110087549A CN 112755029 A CN112755029 A CN 112755029A
Authority
CN
China
Prior art keywords
cells
ranolazine
cancer
riluzole
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110087549.9A
Other languages
English (en)
Chinese (zh)
Inventor
穆斯塔法·比尔金·阿里·贾姆戈兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyrus Oncology Innovation Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110087549.9A priority Critical patent/CN112755029A/zh
Publication of CN112755029A publication Critical patent/CN112755029A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202110087549.9A 2010-10-13 2010-10-13 治疗癌症/抑制转移 Pending CN112755029A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110087549.9A CN112755029A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2010/001908 WO2012049440A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis
CN2010800703488A CN103370060A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移
CN202110087549.9A CN112755029A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800703488A Division CN103370060A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Publications (1)

Publication Number Publication Date
CN112755029A true CN112755029A (zh) 2021-05-07

Family

ID=44022817

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110087549.9A Pending CN112755029A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移
CN2010800703488A Pending CN103370060A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800703488A Pending CN103370060A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Country Status (13)

Country Link
US (5) US20130203764A1 (https=)
EP (4) EP2627321A1 (https=)
JP (1) JP2013539778A (https=)
KR (1) KR20140032346A (https=)
CN (2) CN112755029A (https=)
AU (2) AU2010362412A1 (https=)
BR (1) BR112013009086A2 (https=)
CA (1) CA2851694C (https=)
DK (1) DK3132791T3 (https=)
IL (1) IL225689A0 (https=)
RU (1) RU2013121744A (https=)
SG (1) SG189352A1 (https=)
WO (1) WO2012049440A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013009086A2 (pt) 2010-10-13 2016-07-26 Mustafa Bilgin Ali Djamgoz tratamento de câncer/inibição de metástase
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
WO2017091574A1 (en) * 2015-11-25 2017-06-01 Health Research, Inc. Riluzole and riluzole drug combinations for the treatment of prostate cancer
JP6465306B2 (ja) * 2016-02-04 2019-02-06 セレックス・オンコロジー・リミテッド 癌の治療／転移の阻害
LT3458053T (lt) * 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
AU2018218341B2 (en) * 2017-02-10 2023-07-06 Celex Oncology Innovations Limited Treatment of cancer and inhibition of metastasis
US20200123544A1 (en) * 2018-10-22 2020-04-23 Celex Oncology Innovations Limited Gene therapy targeting the neonatal form of nav1.5 for treating cancer
AU2020370748B2 (en) * 2019-10-24 2025-08-21 Celex Oncology Innovations Limited Combination treatments for cancer
US20230062361A1 (en) 2020-01-21 2023-03-02 Celex Oncology Innovations Limited Monoclonal antibodies against neonatal nav1.5
US20230139204A1 (en) 2020-03-09 2023-05-04 Celex Oncology Innovations Limited Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells
EP4176880A4 (en) * 2020-07-01 2024-07-03 New Cancer Cure - Bio Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A 3-KETOACYL-COA THIOLASE INHIBITOR AND AN INHIBITOR OF CARNITINE ACYLCARNITINE TRANSPORTERS
AU2024357729A1 (en) 2023-10-12 2026-04-09 Celex Oncology Innovations Limited Treatment of metastatic or invasive brain cancer
WO2025252860A1 (en) 2024-06-04 2025-12-11 Celex Oncology Innovations Limited Ranolazine enantiomer for use in cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221246A1 (en) * 2004-04-16 2010-09-02 University Of Medicine And Dentistry Of New Jersey Methods and compositions for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088915A2 (en) * 2002-04-18 2003-10-30 University Of Virginia Patent Foundation Novel sodium channel blockers
WO2004062604A2 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
ES2691411T3 (es) 2006-03-27 2018-11-27 Wex Medical Limited Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
WO2010033581A1 (en) * 2008-09-16 2010-03-25 University Of Washington Molecular modulators of the wnt/beta-catenin pathway
BR112013009086A2 (pt) * 2010-10-13 2016-07-26 Mustafa Bilgin Ali Djamgoz tratamento de câncer/inibição de metástase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221246A1 (en) * 2004-04-16 2010-09-02 University Of Medicine And Dentistry Of New Jersey Methods and compositions for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GING KUO WANG ET AL: "State-and Use-Dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-Gated Na+ Channel Isoforms by Ranolazine", 《MOLECULAR PHARMACOLOGY》, vol. 73, no. 3, 13 December 2007 (2007-12-13), pages 940 - 948 *
JKJ DISS ET AL.: "β-Subunits of voltage-gated sodium channels in human prostate cancer: quantitative in vitro and in vivo analyses of mRNA expression", 《PROSTATE CANCER AND PROSTATIC DISEASES》, vol. 11, 25 September 2007 (2007-09-25), pages 325 - 333 *
SCOTT P. FRASER ET AL: "Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis", 《CLINICAL CANCER RESEARCH》, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5381 - 5389 *
YA-JEAN WANG ET AL: "Riluzole-induced block of voltage-gated Na+ current and activation of BKca channels in cultured differentiated human skeletal muscle cells", 《LIFE SCIENCES》, vol. 82, 2 January 2008 (2008-01-02), pages 11 - 20 *

Also Published As

Publication number Publication date
WO2012049440A1 (en) 2012-04-19
US20160096812A1 (en) 2016-04-07
CA2851694C (en) 2019-02-26
AU2017202267A1 (en) 2017-04-27
US20200017457A1 (en) 2020-01-16
IL225689A0 (en) 2013-06-27
US20130203764A1 (en) 2013-08-08
EP3653206A1 (en) 2020-05-20
JP2013539778A (ja) 2013-10-28
EP2627321A1 (en) 2013-08-21
BR112013009086A2 (pt) 2016-07-26
EP3132791B1 (en) 2019-11-27
EP3132791A1 (en) 2017-02-22
US11634398B2 (en) 2023-04-25
AU2010362412A1 (en) 2013-05-30
US20230202994A1 (en) 2023-06-29
EP4640281A3 (en) 2026-01-07
US12534444B2 (en) 2026-01-27
AU2017202267B2 (en) 2019-01-24
DK3132791T3 (da) 2020-03-09
RU2013121744A (ru) 2014-11-20
US20180346431A1 (en) 2018-12-06
CN103370060A (zh) 2013-10-23
EP4640281A2 (en) 2025-10-29
SG189352A1 (en) 2013-05-31
KR20140032346A (ko) 2014-03-14
CA2851694A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
CN112755029A (zh) 治疗癌症/抑制转移
Guo et al. 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N′-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A
US12605390B2 (en) Treatment of cancer and inhibition of metastasis
Tsukimoto et al. Anti‐inflammatory potential of remimazolam: A laboratory and clinical investigation
Shoaib et al. Metformin-mediated mitochondrial protection post-cardiac arrest improves EEG activity and confers neuroprotection and survival benefit
WO2012049439A1 (en) Treatment of cancer/inhibition of metastasis
JP2019001826A (ja) 癌の治療／転移の阻害
JP6465306B2 (ja) 癌の治療／転移の阻害
JP2022179708A (ja) 癌の治療／転移の阻害
Tschopp et al. Defective platelet adhesion and aggregation on subendothelium exposed in vivo or in vitro to flowing blood of fawn-hooded rats with storage pool disease
Janosi et al. Differential roles of endothelin‐1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung
Cui et al. Ketamine inhibits lung fluid clearance through reducing alveolar sodium transport
GB2484513A (en) Treatment of cancer/inhibition of metasesis using ranolazine or riluzole
Cruz et al. 118 NGF-INDUCE DETRUSOR OVERACTIVITY IS TRPV1 DEPENDENT
Park et al. 116 ARE CLINICALLY INSIGNIFICANT PROSTATE CANCERS REALLY INSIGNIFICANT IN THE KOREAN POPULATION?
Yokovama et al. 117 EFFECTS OF ENCEPHALIN GENE THERAPY USING HERPES SIMPLEX VIRUS VECTOR ON BLADDER HYPERACTIVITYAND NOCICEPTION
Bhardwaj Neuromyogenic properties of the internal anal sphincter: Applications for the treatment of anal fissures

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231206

Address after: London

Applicant after: Cyrus oncology Innovation Co.,Ltd.

Address before: London

Applicant before: Djamgoz Mustafa Bilgin Ali